Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2022 Jan 1.

Published in final edited form as: Alzheimers Dement. 2020 Jul 27;17(1):7–17. doi: 10.1002/alz.12156

Table 4. Pharmacokinetics data.

n=15 for both doses.

Dose	Parameter	Time
Dose	Parameter	0 Minutes	60 Minutes	90 Minutes
500 mg	OAA (ng/ml)	94 (102)	63 (55)	87 (80)
	OAA (normalized)	1.00 (0.00)	1.01 (0.51)	1.15 (0.41)
	Pyruvate (ng/ml)	8298 (3293)	8305 (3532)	7621 (3184)
	Pyruvate (normalized)	1.00 (0.00)	1.00 (0.15)	0.93 (0.14)
	OAA/Pyruvate	0.010 (0.009)	0.007 (0.005)	0.010 (0.007)
	OAA/Pyruvate (normalized)	1.00 (0.00)	1.02 (0.48)	1.30 (0.56)^*
1000 mg	OAA (ng/ml)	1400 (962)	1355 (690)	1363 (759)
	OAA (normalized)	1.00 (0.00)	1.07 (0.20)	0.99 (0.19)
	Pyruvate (ng/ml)	10254 (5045)	9688 (3891)	9200 (3966)
	Pyruvate (normalized)	1.00 (0.00)	0.98 (0.16)	0.93 (0.16)
	OAA/Pyruvate	0.14 (0.06)	0.15 (0.06)	0.16 (0.079)
	OAA/Pyruvate (normalized)	1.00 (0.00)	1.09 (0.17)^*	1.11 (0.30)

^*

p<0.05, unpaired t-test relative to 0 minutes.